New York, New York, United States Related Funds
Funds with similar focus
| Fund Name | Location |
| 1818 Venture Capital | Guernsey, Guernsey, NA - Guernsey |
| Acorn Bioventures | New York, New York, United States |
| Acuity Brands | Atlanta, Georgia, United States |
| Bincot | - |
| Cheval Holdings | - |
| Concord Partners | Massachusetts, United States, Wellesley |
| GeneScience Pharmaceuticals | - |
| Hacking Health Accelerator | Canada, Montréal, Quebec |
| Hermann Companies | Arkansas, Paragould, United States |
| Kissei Pharmaceutical | Japan, Matsumoto, Nagano Prefecture |
| MEST Express accelerator | Accra, Ghana, Greater Accra |
| Old Ironsides Energy | Boston, Massachusetts, United States |
| Ontario Pension Board | Canada, Ontario, Toronto |
| Orgain | California, Irvine, United States |
| Technologies SAS | - |
| Tokyo Commodity Exchange | - |
| Trends Media | - |
| Yiguo Group | Changning, China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Third Harmonic Bio | $105M | 16 Jan 2022 | Cambridge, Massachusetts, United States | ||
Shoreline Biosciences | $43M | 07 Feb 2021 | San Diego, California, United States |
– Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the closing of a $105 million private financing round.
– The round was led by BVF Partners L.P., with participation from existing investors including RA Capital Management and Atlas Venture.
– Access Biotechnology, Commodore Capital, Logos Capital, Surveyor Capital (a Citadel company), and a large alternative asset manager joined as new investors in this financing.
– In addition to the Phase 2 studies of Nimbus’ allosteric TYK2 inhibitor, the financing will support a first-in-human study of the company’s HPK1 inhibitor candidate in cancer patients with solid tumors, which will begin later this year, and will accelerate preclinical programs against multiple targets in oncology and immunology.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Third Harmonic Bio | $105M | 16 Jan 2022 | Cambridge, Massachusetts, United States | ||
Shoreline Biosciences | $43M | 07 Feb 2021 | San Diego, California, United States |
